BIO 2025: Making Biologics Manufacturing Accessible
In this BIO 2025 preview interview, The Pharma Navigator looks at continuous biologics manufacturing in greater detail with Russell Miller from Enzene Biosciences.
Biologics are gaining popularity thanks to their ability to treat, oftentimes, difficult-to-treat illnesses. However, these therapies are highly complex and sensitive, meaning their manufacture can be a cost-intensive process.
“There are a lot of innovative approaches to enabling biologics manufacturing,” specifies Russell Miller, vice president of global sales and marketing at Enzene Biosciences — a CDMO that offers fully integrated services. Prior to moving into the CDMO space, Miller explains that Enzene started out as a biosimiliar product development company, during which time the company sought out ways to innovate to improve patient access to biologics-based drugs.
“In that time frame, we developed the EnzeneX platform, which is a fully connected continuous manufacturing technology that, as we have found during internal studies, has the opportunity to enhance productivity up to 10 times and reduce the cost of goods by 50%,” Miller says. “Additionally, the platform enhances product quality, especially for complex biotherapeutics, and the other really interesting thing is because the technology is so effective it can be operated on a much smaller footprint, so its environmental impact is also positive when compared with other traditional biologics manufacturing.”
To broaden access to the fully connected continuous manufacturing platform to small and mid-sized biotech companies, the company opened a manufacturing facility in Hopewell, N.J. (1). “We wanted to bring the technology to the U.S., to enable folks to take advantage of this platform,” Miller confirms. “Our N.J. facility has two initial suites, fully capable of doing either traditional fed batches, because we know that not everybody is there yet in continuous, and also has the opportunity to support our EnzeneX 1.0 and 2.0 platforms with the fully connected continuous manufacturing technology.”
Click the video above to view the full interview
Reference
Enzene. Enzene Biosciences Launches First Manufacturing Base in the U.S., at its New Jersey Site. Press Release, Jan. 8, 2024.
Music from #Uppbeat (free for Creators!):
https://uppbeat.io/t/richard-smithson/air
License code: QHDAN9DIKVMQW8EK